Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Otsuka Pharmaceutical Co., Ltd.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient has a history of migraine (according to the ICHD-3 criteria) diagnosis for ≥12 months prior to giving informed consent.
Patient fulfills any of the migraine criteria(according to the ICHD-3 criteria) on ≥4 days in baseline information collected during the 28-day screening period
You may not be if
History of hypersensitivity reactions to injected proteins, including monoclonal antibodies
Prior exposure to a monoclonal antibody targeting (CGRP) pathway meeting the following conditions:
* Less than 5 months has passed since the final administration of AMG334, ALD304, or LY2951742.
* Less than 1 year has passed since the final administration of TEV-48125
